奥浦迈股价跌5.15%，工银瑞信基金旗下1只基金位居十大流通股东，持有290.01万股浮亏损失870.03万元

Group 1 - The core viewpoint of the news is that Aopumai's stock price has declined by 5.15%, currently trading at 55.27 CNY per share, with a total market capitalization of 6.276 billion CNY [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company specializes in cell culture products and services, with revenue composition being 87.34% from products, 12.53% from services, and 0.13% from other sources [1] - The trading volume for Aopumai was 48.9595 million CNY, with a turnover rate of 1.11% [1] Group 2 - Among Aopumai's top ten circulating shareholders, a fund under ICBC Credit Suisse Asset Management has increased its holdings in Aopumai by 1.2508 million shares, now holding a total of 2.9001 million shares, which accounts for 3.75% of the circulating shares [2] - The fund, ICBC Frontier Medical Stock A (001717), has a current scale of 9.33 billion CNY and has achieved a year-to-date return of 37.86%, ranking 607 out of 4222 in its category [2] - The fund manager, Zhao Bei, has been in the position for 10 years and 285 days, with the fund's best return during this period being 262.7% [2]